Suppr超能文献

静脉内丁丙诺啡和去甲丁丙诺啡在人体内的药代动力学。

Intravenous buprenorphine and norbuprenorphine pharmacokinetics in humans.

机构信息

Chemistry and Drug Metabolism, Intramural Research Program, National Institute on Drug Abuse, National Institutes of Health, 251 Bayview Boulevard, Baltimore, MD 21224, USA.

出版信息

Drug Alcohol Depend. 2013 Aug 1;131(3):258-62. doi: 10.1016/j.drugalcdep.2012.11.014. Epub 2012 Dec 14.

Abstract

BACKGROUND

Prescribed sublingual (SL) buprenorphine is sometimes diverted for intravenous (IV) abuse, but no human pharmacokinetic data are available following high-dose IV buprenorphine.

METHODS

Plasma was collected for 72 h after administration of placebo or 2, 4, 8, 12, or 16 mg IV buprenorphine in escalating order (single-blind, double-dummy) in 5 healthy male non-dependent opioid users. Buprenorphine and its primary active metabolite, norbuprenorphine, were quantified by liquid chromatography-tandem mass spectrometry with limits of quantitation of 0.1 μg/L.

RESULTS

Maximum buprenorphine concentrations (mean ± SE) were detected 10 min after 2, 4, 8, 12, 16 mg IV: 19.3 ± 1.0, 44.5 ± 4.8, 85.2 ± 7.7, 124.6 ± 16.6, and 137.7 ± 18.8 μg/L, respectively. Maximum norbuprenorphine concentrations occurred 10-15 min (3.7 ± 0.7 μg/L) after 16 mg IV administration.

CONCLUSIONS

Buprenorphine concentrations increased in a significantly linear dose-dependent manner up to 12 mg IV buprenorphine. Thus, previously demonstrated pharmacodynamic ceiling effects (over 2-16 mg) are not due to pharmacokinetic adaptations within this range, although they may play a role at doses higher than 12 mg.

摘要

背景

处方舌下(SL)丁丙诺啡有时会被转移用于静脉内(IV)滥用,但尚无人类药代动力学数据可用于高剂量 IV 丁丙诺啡后。

方法

在 5 名健康的非依赖阿片类药物男性使用者中,以递增顺序(单盲,双盲)单次给予安慰剂或 2、4、8、12 或 16 mg IV 丁丙诺啡后,收集 72 小时的血浆。丁丙诺啡及其主要活性代谢物去甲丁丙诺啡通过液相色谱-串联质谱法进行定量,定量下限为 0.1 μg/L。

结果

10 分钟后检测到最大丁丙诺啡浓度(平均值±SE):2、4、8、12、16 mg IV 分别为 19.3±1.0、44.5±4.8、85.2±7.7、124.6±16.6 和 137.7±18.8μg/L。最大去甲丁丙诺啡浓度在 16 mg IV 给药后 10-15 分钟出现(3.7±0.7μg/L)。

结论

丁丙诺啡浓度呈显著线性剂量依赖性增加,直至 12 mg IV 丁丙诺啡。因此,先前表现出的药效学上限效应(2-16 mg 之间)不是由于在此范围内的药代动力学适应引起的,尽管它们在剂量高于 12 mg 时可能起作用。

相似文献

1
Intravenous buprenorphine and norbuprenorphine pharmacokinetics in humans.
Drug Alcohol Depend. 2013 Aug 1;131(3):258-62. doi: 10.1016/j.drugalcdep.2012.11.014. Epub 2012 Dec 14.
2
Human pharmacokinetics of intravenous, sublingual, and buccal buprenorphine.
J Anal Toxicol. 1996 Oct;20(6):369-78. doi: 10.1093/jat/20.6.369.
5
Intravenous and sublingual buprenorphine in horses: pharmacokinetics and influence of sampling site.
Vet Anaesth Analg. 2011 Jul;38(4):374-84. doi: 10.1111/j.1467-2995.2011.00613.x. Epub 2011 Apr 19.
8
Pharmacokinetic-pharmacodynamic modelling of intravenous buprenorphine in conscious horses.
Vet Anaesth Analg. 2015 Jan;42(1):17-29. doi: 10.1111/vaa.12165. Epub 2014 Apr 16.

引用本文的文献

1
Pharmacogenomics of buprenorphine - a narrative review.
Pharmacogenomics. 2025 May-Jun;26(7-9):263-270. doi: 10.1080/14622416.2025.2546770. Epub 2025 Sep 5.
6
Nalmefene Hydrochloride: Potential Implications for Treating Alcohol and Opioid Use Disorder.
Subst Abuse Rehabil. 2024 Apr 3;15:43-57. doi: 10.2147/SAR.S431270. eCollection 2024.
8
In Vitro-In Vivo Correlation of Buprenorphine Transdermal Systems Under Normal and Elevated Skin Temperature.
Pharm Res. 2023 May;40(5):1249-1258. doi: 10.1007/s11095-023-03487-z. Epub 2023 Apr 24.
9
Respiratory effects of oral mitragynine and oxycodone in a rodent model.
Psychopharmacology (Berl). 2022 Dec;239(12):3793-3804. doi: 10.1007/s00213-022-06244-z. Epub 2022 Oct 29.

本文引用的文献

1
Misuse of buprenorphine maintenance treatment since introduction of its generic forms: OPPIDUM survey.
Pharmacoepidemiol Drug Saf. 2012 Feb;21(2):184-90. doi: 10.1002/pds.2263. Epub 2011 Nov 23.
2
Illicit use of buprenorphine/naloxone among injecting and noninjecting opioid users.
J Addict Med. 2011 Sep;5(3):175-80. doi: 10.1097/ADM.0b013e3182034e31.
3
Gender differences in pharmacokinetics of maintenance dosed buprenorphine.
Drug Alcohol Depend. 2011 Nov 1;118(2-3):479-83. doi: 10.1016/j.drugalcdep.2011.03.024. Epub 2011 Apr 23.
4
Injection of buprenorphine and buprenorphine/naloxone tablets in Malaysia.
Drug Alcohol Depend. 2010 Sep 1;111(1-2):44-9. doi: 10.1016/j.drugalcdep.2010.03.014. Epub 2010 May 15.
5
Intravenous misuse of buprenorphine: characteristics and extent among patients undergoing drug maintenance therapy.
Clin Drug Investig. 2010;30 Suppl 1:3-11. doi: 10.2165/11536020-000000000-00000.
7
Why do the clients of Georgian needle exchange programmes inject buprenorphine?
Eur Addict Res. 2010;16(1):1-8. doi: 10.1159/000253858. Epub 2009 Nov 2.
8
Abuse liability of buprenorphine-naloxone tablets in untreated IV drug users.
Drug Alcohol Depend. 2007 Apr 17;88(1):75-8. doi: 10.1016/j.drugalcdep.2006.09.012. Epub 2006 Oct 19.
10
Effects of high-dose intravenous buprenorphine in experienced opioid abusers.
J Clin Psychopharmacol. 2004 Oct;24(5):479-87. doi: 10.1097/01.jcp.0000138766.15858.c6.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验